Anti-Cancer Therapies that Utilize Cell Penetrating Peptides

Author(s): Benjamin G. Bitler, Joyce A. Schroeder.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 5 , Issue 2 , 2010

Become EABM
Become Reviewer

Abstract:

Cell penetrating peptides (CPPs) are 9-35mer cationic and/or amphipathic peptides that are rapidly internalized across cell membranes. Importantly, they can be linked to a variety of cargo, including anti-cancer therapeutics, making CPPs an efficient, effective and non-toxic mechanism for drug delivery. In this review, we discuss a number of CPP conjugated therapies (CTTs) that are either patented are in the progress of patenting, and show strong promise for clinical efficacy. The CTTs discussed here target a number of different processes specific to cancer progression, including proliferation, survival and migration. In addition, many of these CTTs also increase sensitivity to current anti-cancer therapy modalities, including radiation and other DNA damaging chemotherapies, thereby decreasing the toxic dosage required for effective treatment. Mechanistically, these CTTs function in a dominant-negative manner by blocking tumorspecific protein-protein interactions with the CPP-conjugated peptide or protein. The treatment of both cell lines and mouse models demonstrates that this method of molecular targeting results in equal if not greater efficacy than current standards of care, including DNA damaging agents and topoisomerase inhibitors. For the treatment of invasive carcinoma, these CTTs have significant clinical potential to deliver highly targeted therapies without sacrificing the patients quality of life.

Keywords: Cell penetrating peptides, protein transduction domain, Tat, targeted therapies, patent

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 2
Year: 2010
Page: [99 - 108]
Pages: 10
DOI: 10.2174/157489210790936252
Price: $58

Article Metrics

PDF: 14